clinical trial · NCT07374848
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Zai Lab (Shanghai) Co., Ltd.·phase1·recruiting·n = 180
Solid TumorsSarcomasZL-6201
brief summary
The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
started
Mar 1, 2026
primary completion
Aug 1, 2028
completion
Sep 1, 2029
last updated
Mar 5, 2026
detailed description
An Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants with Sarcoma and Selected Solid Tumors
official title
An Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol